Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Thierry Conroy reports on key results from ESMO Congress 2021 on LBA57 - Unicancer GI PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter randomized phase 3 trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas.
19 Sep 2021 Proffered Paper session - Gastrointestinal tumours, non-colorectal
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
